Literature DB >> 15198452

A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine.

David Fortin1, Robert Adams, Ariane Gallez.   

Abstract

OBJECTIVE: We propose a simple modification to an established blood-brain barrier disruption (BBBD) animal model that allows us to use ketamine/xylazine as the anaesthetic agent, therefore decreasing the complexity and the cost of the model, while maintaining similar efficiency.
METHODS: Sixty-two Long Evans rats were anaesthetized by intraperitoneal injection of ketamine/xylazine. Osmotic BBBD was performed by administering 25% mannitol into the internal carotid artery in a retrograde fashion from the external carotid. The infusion rate of mannitol, as well as the duration was adjusted in a stepwise fashion to identify optimal parameters for BBBD and minimize complications. As a supplementary step to previously reported models, a vascular clip was applied to the common carotid artery prior to the infusion of mannitol, therefore isolating our model system from the depressant hemodynamic effects of ketamine/xylazine. Evans blue dye was used to control for BBBD intensity.
RESULTS: Using this model at an initial infusion rate of 0.15 ml/sec, a significant incidence of brain hemorrhage (75%) and a death rate of 62.5% were observed. Decreasing the infusion rate in a stepwise fashion, 0.08 ml/sec was found to produce optimal BBBD, as demonstrated by Evans blue staining. At this rate, 6/7 animals depicted grade II staining, whereas one animal depicted grade IV.
CONCLUSION: The application of a clip to the common carotid artery prior to mannitol infusion allowed us to isolate the cerebral circulation from the depressant hemodynamic effects of ketamine/xylazine. This supplementary step produced consistent and efficient BBBD in our animal model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198452     DOI: 10.1017/s0317167100053890

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  5 in total

1.  Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  J Neurooncol       Date:  2013-09-13       Impact factor: 4.130

2.  Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

Review 3.  Recent advances in blood-brain barrier disruption as a CNS delivery strategy.

Authors:  Marc-André Bellavance; Marie Blanchette; David Fortin
Journal:  AAPS J       Date:  2008-03-18       Impact factor: 4.009

4.  Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglycerol-mediated transfer to the brain.

Authors:  Petra Hülper; Christian Dullin; Wilfried Kugler; Max Lakomek; Bernhard Erdlenbruch
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

5.  Neurosteroids and GABA-A Receptor Function.

Authors:  Mingde Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-04       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.